Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Longeveron Inc. Common Stock (LGVN)

Pharmaceutical Preparations

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.

1951 NW 7TH AVENUE, SUITE 520
MIAMI, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/12/2021

Market Cap

33,459,017

Shares Outstanding

10,250,000

Weighted SO

25,107,303

Total Employees

N/A

Upcoming Earnings

08/09/2024

Similar Tickers

NTRB --.--%

QNRX --.--%

RNXT --.--%

VRAX --.--%

GBIO --.--%

KRON --.--%

ERAS --.--%

CCCC --.--%

EWTX --.--%

Beta

0.4210

Last Div

0.0000

Range

0.771-35.6

Chg

-0.1299

Avg Vol

10856095

Mkt Cap

33459017

Exch

NASDAQ

Country

US

Phone

305 909 0840

DCF Diff

3.3320

DCF

-0.9920

Div Yield

0.0000

P/S

27.2246

EV Multiple

-1.2254

P/FV

1017.2808

Div Yield %

0.0000

P/E

-543.6021

PEG

103.8391

Payout

0.0000

Current Ratio

4.1776

Quick Ratio

4.1776

Cash Ratio

3.8551

DSO

64.7437

DIO

0.0000

Op Cycle

64.7437

DPO

220.5438

CCC

-155.8001

Gross Margin

0.1920

Op Margin

-14.8015

Pretax Margin

-22.7046

Net Margin

-22.7046

Eff Tax Rate

-0.0100

ROA

-1.4389

ROE

-3.5518

ROCE

-1.1241

NI/EBT

1.0000

EBT/EBIT

1.5339

EBIT/Rev

-14.8015

Debt Ratio

0.0314

D/E

0.0408

LT Debt/Cap

0.0000

Total Debt/Cap

0.0392

Int Coverage

-263.6377

CF/Debt

-19.1431

Equity Multi

1.3006

Rec Turnover

5.6376

Pay Turnover

1.6550

Inv Turnover

0.0000

FA Turnover

0.3587

Asset Turnover

0.0634

OCF/Share

-0.0018

FCF/Share

-0.0019

Cash/Share

0.0019

OCF/Sales

-9.4703

FCF/OCF

1.0362

CF Coverage

-19.1431

ST Coverage

-19.1431

CapEx Coverage

-27.6461

Div&CapEx Cov

-27.6461

P/BV

1017.2808

P/B

1017.2808

P/S

27.2246

P/E

-543.6021

P/FCF

-2.7744

P/OCF

-1303.2626

P/CF

-1303.2626

PEG

103.8391

P/S

27.2246

EV Multiple

-1.2254

P/FV

1017.2808

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 27, 19:10 Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting GlobeNewswire Inc. Jul 28, 20:51 Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) GlobeNewswire Inc. Dec 22, 16:05 Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. Dec 21, 10:34 UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. Nov 11, 09:00 Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association GlobeNewswire Inc. Nov 11, 09:00 Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association GlobeNewswire Inc. Nov 10, 07:30 Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

Revenue Product Segmentation